Abstract: The invention provides a hydrosol of a pharmacological active agent in an intravenous applicable, stabilised, pharmaceutically acceptable form, which form is suspended or is dry and re-suspendable in an aqueous medium.The hydrosol contains solid active agent particles, e.g. of dihydropyridines or cyclosporines.

Abstract: Compounds of the formula ##STR1## and salts thereof, and mixtures of such compounds and salts, wherein F.sub.c is ##STR2## wherein D.sub.1 is an unsubstituted or substituted phenyl or naphthyl diazo component radical,each of Q.sub.1, Q.sub.2 and Q.sub.3 is independently hydrogen or a substituent,each R.sub.5 is independently hydrogen, C.sub.1-4 alkyl or C.sub.1-4 alkoxy,each R.sub.6 is independently hydrogen, halo, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, (C.sub.1-4 alkyl)carbonylamino or --NH--CO--NH.sub.2,R.sub.16 is hydrogen or --SO.sub.3 H,r is 1 or 2, andt is 2 or 3, andb is 1 or 2,whereineach R.sub.1 is independently hydrogen or C.sub.1-4 alkyl,each R.sub.7 is independently hydroxy, C.sub.1-4 alkoxy or --NH.sub.2,each Z is independently ##STR3## and each m is independently 0 or 1.

Abstract: Compound of the formula ##STR1## where R is CH.sub.3 (CH.sub.2).sub.m, A and B are hydrogen, a bond or --(CH.sub.2).sub.n,X is ##STR2## m is 0, 1 , 2 or 3, n is 1 , 2, or 3, R.sub.1 is hydrogen or lower alkyl, andY is --OH, --OR.sub.2 or --NR.sub.3 R.sub.4where R.sub.2, R.sub.3 and R.sub.4 are hydrogen or unsubstituted or substituted alkyl, aryl and aralkyl substituents.

Abstract: New use of 11,28-dioxa-4-azatricyclo[22.3.1.0.sup.4,9 ]octacos-18-ene derivatives and pharmaceutical compositions containing themThe compounds of formula I, ##STR1## have been found to have excellent topical activity. They are thus indicated for use in the topical treatment of inflammatory and hyperpoliferative skin diseases and of cutaneous manifestations of immunologically-induced illnesses, such as psoriasis.

Abstract: The present invention provides a pharmaceutical composition for the transdermal systemic administration of an active agent characterized in that the active agent is bopindolol or methysergide. Also the present invention provides a pharmaceutical composition for the transdermal systemic administration of a pharmacologically active agent characterized in that it contains bopindolol, tizanidine, clemastine, ketotifen or methysergide as active agent in a reservoir comprising a hydrophilic polymer. Furthermore a pharmaceutical composition for the transdermal systemic administration of pharmacologically active agents characterised in that the pharmacologically active agent is in a reservoir comprising a polyacrylate polymer containing cationic ester groups.

Abstract: Compounds of the formula ##STR1## wherein one of R and R.sub.o is ##STR2## and the other is primary or secondary C.sub.1-6 alkyl not containing an asymmetric carbon atom, C.sub.3-6 cycloalkyl or phenyl-(CH.sub.2).sub.m --,whereinR.sub.4 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, C.sub.1-3 alkoxy, n-butoxy, i-butoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,R.sub.5 is hydrogen, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, trifluoromethyl, fluoro, chloro, phenoxy or benzyloxy,R.sub.5a is hydrogen, C.sub.1-2 alkyl, C.sub.1-2 alkoxy, fluoro or chloro, andm is 1, 2 or 3, with the provisos that both R.sub.5 and R.sub.5a must be hydrogen when R.sub.4 is hydrogen, R.sub.5a must be hydrogen when R.sub.5 is hydrogen, not more than one of R.sub.4 and R.sub.5 is trifluoromethyl, not more than one of R.sub.4 and R.sub.5 is phenoxy, and not more than one of R.sub.4 and R.sub.5 is benzyloxy,R.sub.2 is hydrogen, C.sub.1-3 alkyl, n-butyl, i-butyl, t-butyl, C.sub.3-6 cycloalkyl, C.sub.

Abstract: Anionic disazo compounds of the formula ##STR1## and salts thereof each cation of which is independently a non-chromophoric cation, and mixtures of such compounds or salts, wherein D is whereinR.sub.4 is hydrogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy or halo,R.sub.1 is hydrogen, C.sub.1-4 alkyl or C.sub.2-4 hydroxyalkyl,R.sub.2 is hydrogen, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, (C.sub.1-4 alkyl)carbonylamino, (C.sub.1-4 alkoxy)carbonylamino or --NHCONH.sub.2,R.sub.3 is hydrogen, halo, C.sub.1-4 alkyl or C.sub.1-4 alkoxy, and ##STR2## wherein R.sub.5 is chloro, hydroxy or --NHCN,R.sub.6 is hydrogen, chloro or cyano, andR.sub.7 and R.sub.8 are as defined in the specification, with the proviso that R.sub.7 and R.sub.8 together contain at least 8 carbon atoms,useful for dyeing or printing anionically dyeable organic substrates such as nitrogen-containing substrates, particularly fiber material comprising natural or synthetic polyamide.

Abstract: The invention concerns the compounds of formula I ##STR1## wherein the substituents have various significances. They are prepared by several processes including epimerizing replacement, treatment with cyanogen bromide or thiophosgene, treatment with an acid having a non-nucleophilic anion, treatment with dimethylsulfoxide and acetic anhydride, acylation, treatment with an oxalyl derivative and ammonia, methylation, oxidation, deprotection and protection.They possess interesting pharmacological activity as antiinflammatory, immunosuppressant, antiproliferative and chemotherapeutic drug resistance reversing agents.

Abstract: Metal-free compounds of the formula ##STR1## and 1:1 and 1:2 metal complexes thereof and acid addition salts of such metal-free compounds and 1:1 and 1:2 metal complexes,whereineach B is --A.sub.1 --NR.sub.7 R.sub.8 or --A.sub.1 --.sup..sym. NR.sub.7 R.sub.8 R.sub.9 A.sup..crclbar., the two B's being identical,whereineach A.sub.1 is linear or branched C.sub.2-8 alkylene,each R.sub.1 is hydrogen, C.sub.1-4 alkyl, C.sub.5-6 cycloalkyl, phenyl, benzyl or phenylethyl, the two R.sub.1 's being identical,each R.sub.2 is independently halo, hydroxy, nitro, carboxy, C.sub.1-4 alkyl or C.sub.1-4 alkoxy,each T is hydrogen, cyano, --COOR.sub.4, --CON(R.sub.5).sub.2, --SO.sub.2 N(R.sub.5).sub.2,the two T's being identical, ##STR2## wherein each R.sub.3 is independently hydrogen, C.sub.1-4 alkyl, --N(R.sub.5).sub.2 or --CON(R.sub.5).sub.2,each R.sub.4 is C.sub.1-6 alkyl or phenyl(C.sub.1-3 alkyl),each R.sub.6 is C.sub.1-4 alkyl, andeach X.sub.a is --O--, --S-- or --NR.sub.5 --, andX.sub.

Abstract: Pharmaceutical compositions comprising a cyclosporin, e.g. Ciclosporin or [Nva].sup.2 -Ciclosporin, in "microemulsion pre-concentrate" and microemulsion form. The compositions typically comprise (1.1) a C.sub.1-5 alkyl or tetrahydrofurfuryl di- or partial-ether of a low molecular weight mono- or poly-oxy-alkane diol, e.g. Transcutol or Glycofurol, as hydrophilic component. Compositions are also provided comprising a cyclosporin and (1.1) and, suitably, also a saccharide monoester, e.g. raffinose or saccharose monolaurate. Dosage forms include topical formulations and, in particular, oral dosage forms.

Abstract: An inhaler for delivering metered doses of a particulate drug. The inhaler is formed of a housing, a drug reservoir attached to the housing to contain multiple doses of the particulate drug, a drug transporting slide in the housing that contains a metering chamber of volume corresponding to a desired dose of the drug, and a vacuum pump that creates a partial vacuum in the metering chamber. The drug transporting slide is movable from a load position, in which it communicates with the drug reservoir to receive in its metering chamber drug from the drug reservoir, to a release position in which it communicates with an air outlet passage to release drug from the metering chamber into the air outlet passage. The drug reservoir has an air permeable portion that permits air flow into the drug reservoir but prevents drug escape. In use, the vacuum pump draws a dose of drug into the metering chamber. The drug transporting slide then moves to deposit the drug in the outlet passage for inhalation.

Abstract: A process for preparing the (R) stereoisomer of 2,2-bis(hydroxmethyl)-tetrahydrofuran monobutyrate comprising subjecting the dibutyric ester of the 2,2-bis(hydroxymethyl)-tetrahydrofuran to enzymatic hydrolysis. The invention also relates to the novel (R) stereoisomer prepared by the instant process and to its more stable forms. In addition, the invention relates to the use of the (R) stereoisomer in preparing stereoisomers of pharmacologically active compounds and to certain specific stereoisomers produced thereby.

Abstract: A process for preparing carboxylates of polyoxyalkylene siloxanes and -amines, alkylpolyoxyalkylenes, polyoxyalkylene block polymers, alkylamidepolyoxyalkylenes and alkylpolyglucosides comprising subjecting a primary hydroxyl group-containing polyoxyalkylene compound or alkylpolyglucoside to mild oxidiation. The invention also relates to the novel polyoxyalkylene amine and alkylamidepolyoxyalkylene carboxylates prepared by the process.

Abstract: This invention relates to a hard gelatin capsule containing no more than 5 to 10 milligrams of crystalline temazepam and its use in the treatment of transient insomnia.

Abstract: Compounds of the formula ##STR1## wherein R.sub.1 is C.sub.1-18 alkyl, substituted C.sub.1-18 alkyl, phenyl, substituted phenyl, C.sub.3-6 alkenyl, substituted C.sub.3-6 alkenyl, C.sub.3-6 alkynyl or substituted C.sub.3-6 alkynyl,R.sub.2 is an electron withdrawing substituent; andK is the residue of a coupling component that is free of any water solubilizing groups.The compounds are disperse dyes which can be used to dye, print or pad fully synthetic or semi-synthetic hydrophobic high molecular weight organic material.

Abstract: Retaining device for patient feeding set to prevent unintentional disconnect of the feeding solution supply tube from the feeding tube.

Abstract: The invention discloses certain substituted .alpha.-aminoacids having the formula ##STR1## where m and n are 1 or 2, and R, R.sub.1, R.sub.2, R.sub.3 and Y have various significances, which compounds are useful in treating epilepsy, disorders associated with excess GH or LH secretion, anxiety, schizophrenia, depression, CNS degenerative disorders, cerebral hypoxic conditions and stress-related psychiatric disorders.

Abstract: Mixtures of iron complexes of metallizable disazo compounds, at least one compound being of the formula ##STR1## and at least one compound being of the formula ##STR2## wherein the substituents have the meaning given in the specification, are useful for dyeing substrates dyeable with anionic dyes, e.g., leather.

Abstract: N-oxy substituted imidic acid derivative of the formula ##STR1## where R.sub.1, R.sub.2 and R.sub.3 are alkyl and aryl substituents, which are useful as antidiabetic and hypolipidemic agents are prepared by the following procedure: ##STR2## where X is chlorine, bromine, or iodine, and R.sub.1 ' is the same as R.sub.1 but with any hydroxy or carboxy groups present protected by a hydroxy or carboxy protecting group and, when R.sub.1 ' is a protected hydroxy or carboxy substituent, deprotecting the substituent.